CeriBell, Inc. (NASDAQ:CBLL) Given Consensus Rating of “Moderate Buy” by Analysts

CeriBell, Inc. (NASDAQ:CBLL) has been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $22.20.

A number of analysts have recently weighed in on CBLL shares. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 29th. Canaccord Genuity Group cut their price objective on CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th.

CeriBell Price Performance

Shares of CeriBell stock remained flat at $19.55 on Friday. 721,324 shares of the stock traded hands, compared to its average volume of 373,296. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.01 and a current ratio of 10.44. CeriBell has a 1 year low of $10.85 and a 1 year high of $24.33. The firm has a market cap of $741.79 million, a PE ratio of -11.99 and a beta of 0.77. The firm has a 50 day moving average of $18.78 and a 200-day moving average of $19.72.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). The firm had revenue of $26.49 million for the quarter, compared to the consensus estimate of $26.09 million. CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. As a group, equities analysts predict that CeriBell will post -1.69 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director William W. Burke sold 2,207 shares of CeriBell stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $19.84, for a total transaction of $43,786.88. Following the sale, the director owned 23,022 shares of the company’s stock, valued at approximately $456,756.48. The trade was a 8.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Joseph Michael Taylor sold 5,500 shares of the stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $18.41, for a total transaction of $101,255.00. Following the completion of the transaction, the director directly owned 61,573 shares of the company’s stock, valued at approximately $1,133,558.93. The trade was a 8.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 350,789 shares of company stock valued at $6,887,691 over the last quarter. 20.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Strs Ohio purchased a new stake in shares of CeriBell in the 1st quarter worth about $27,000. Caitong International Asset Management Co. Ltd increased its holdings in CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after buying an additional 1,231 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in CeriBell in the 3rd quarter worth about $33,000. CWM LLC lifted its stake in CeriBell by 1,178.5% during the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after acquiring an additional 1,697 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after acquiring an additional 1,801 shares during the last quarter.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.